X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

OncoImmunology

期刊標題檢索 ONCOIMMUNOLOGY 最新評論: Submitted on August 1, 2023, received first round of major revision ... (2024-03-05)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[OncoImmunology]您好,您是該頁面的第 50217 位訪客。

期刊簡介
期刊名稱OncoImmunology OncoImmunology
LetPub Score
7.8
50 ratings
Rate

Reputation
8.8

Influence
6.8

Speed
9.4

期刊簡稱ONCOIMMUNOLOGY
ISSN2162-4011
E-ISSN2162-402X
h-index58
CiteScore
CiteScoreSJRSNIPCiteScore Rank
12.802.3450.987
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q140 / 404
Category: Medicine
Subcategory: Immunology and Allergy
Q130 / 233
Category: Medicine
Subcategory: Immunology
Q134 / 236

自引率 (2023-2024)3.10%自引率趨勢
掲載範囲
Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.
OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.
官方網站http://www.tandfonline.com/loi/koni20
在線稿件提交https://www.editorialmanager.com/ONCOIMM
開放訪問No
出版商Landes Bioscience
主題領域ONCOLOGY
出版國/地區UNITED STATES
發行頻率
創刊年0
每年文章數114每年文章數趨勢
黃金OA百分比100.00%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
IMMUNOLOGYSCIEQ130/181
ONCOLOGYSCIEQ144/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2162-4011%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 24 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【OncoImmunology】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Science ImmunologyH-index: 0

    CiteScore: 32.90
    Journal of Allergy and Clinical Immunology-In PracticeH-index: 40

    CiteScore: 11.10
    Cancer Immunology ResearchH-index: 62

    CiteScore: 15.60
    npj VaccinesH-index: 8

    CiteScore: 11.90
    OncoImmunologyH-index: 49

    CiteScore: 12.80
    ALLERGOLOGY INTERNATIONALH-index: 45

    CiteScore: 12.60
    HLAH-index: 93

    CiteScore: 3.00
    Immunity & AgeingH-index: 38

    CiteScore: 10.20
    Clinical and Translational AllergyH-index: 28

    CiteScore: 7.50
    Immune NetworkH-index: 11

    CiteScore: 10.30
    學科內最受檢索的期刊 頁面查看次數
    Journal of Inflammation Research74002
    Cancer Immunology Research57106
    OncoImmunology54803
    Science Immunology39870
    npj Vaccines29223
    Human Vaccines & Immunotherapeutics24480
    Human Vaccines & Immunotherapeutics24446
    Endocrine Metabolic & Immune Disorders-Drug Targets20779
    Journal of Allergy and Clinical Immunology-In Practice18703
    Allergy Asthma & Immunology Research18484
  •  

    OncoImmunology OncoImmunology
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [OncoImmunology] 的評論撰寫評論
作者: Journals


領域: 医学
審稿時間: 2.0 month(s)
結果: 修改後接受


撰寫評論

2024-03-05 11:10:41 評論於
Submitted on August 1, 2023, received first round of major revision comments after 2 months; revised and sent back after 1 month, no time limit set for reviewers to continue review; received second round of major revision comments after 1 and a half months; revised after 1 month, received minor revision comments after around 1 month, and accepted after 3 days. Review was rigorous and feedback was constructive, a great opportunity to humbly learn true knowledge
(0) 讚! | Journals

作者: ILOVER


領域: 医学
審稿時間: 2.0 month(s)
結果: 修改後接受


撰寫評論

2020-12-23 08:20:07 評論於
Submitted at the end of August, and accepted at the end of December. During this period, it underwent a major revision, but without supplementing experiments, only answering the reviewer's questions. We delayed it and resubmitted the revision only after more than a month, and then it was directly accepted after two days. The overall feeling is quite good, processing and reviewing manuscripts are very fast, the impact factor is not bad, and you can try more in the future.

(0) 讚! | ILOVER

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [OncoImmunology] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*